{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:30:11Z","timestamp":1790829011339,"version":"4.1.0"},"reference-count":26,"publisher":"Walter de Gruyter GmbH","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2017-0456_s_999_w2aab3b7c10b1b6b1aab1c16b1Aa\">\n                  <jats:title>Background:<\/jats:title>\n                  <jats:p>A new ELISA for autoantibodies to steroid 21-hydroxylase (21-OH Ab) is described.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2017-0456_s_998_w2aab3b7c10b1b6b1aab1c16b2Aa\">\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>In the assay test sample autoantibodies form a bridge between 21-OH coated onto the plate well and liquid phase 21-OH-biotin. Bound 21-OH-biotin is detected by the addition of streptavidin peroxidase and colorogenic peroxidase substrate.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2017-0456_s_997_w2aab3b7c10b1b6b1aab1c16b3Aa\">\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>Of 100 samples from patients with autoimmune Addison\u2019s disease, 86 (86%) were positive for 21-OH Ab ELISA whereas 84 (84%) were positive in an immunoprecipitation assay based on <jats:sup>125<\/jats:sup>I-labeled 21-OH. Six (0.6%) of 928 healthy adult blood donors and 1 (2.0%) of 49 adult patients with type 1 diabetes mellitus (T1DM) were positive by ELISA. No samples from adult patients with Graves\u2019 disease (GD; n=50), celiac disease (n=29), systemic lupus erythematosis (n=9) or rheumatoid arthritis (n=20) were positive by ELISA. However, 2\/51 (3.9%) children with GD, 3\/69 (4.3%) children with Hashimoto\u2019s thyroiditis (HT) and 3\/119 (2.5%) children with T1DM alone or associated with autoimmune thyroid disorders were ELISA positive.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2017-0456_s_996_w2aab3b7c10b1b6b1aab1c16b4Aa\">\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p>The new assay should be useful for screening patients known to be at increased risk of developing clinical autoimmune Addison\u2019s disease, in particular children with HT, GD and\/or T1DM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2017-0456","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T22:16:29Z","timestamp":1513894589000},"page":"933-938","source":"Crossref","is-referenced-by-count":17,"title":["A new ELISA for autoantibodies to steroid 21-hydroxylase"],"prefix":"10.1515","volume":"56","author":[{"given":"Maria","family":"del Pilar Larosa","sequence":"first","affiliation":[{"name":"FIRS Laboratories, RSR Ltd., Parc Ty Glas, Llanishen , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Chen","sequence":"additional","affiliation":[{"name":"FIRS Laboratories, RSR Ltd., Parc Ty Glas, Llanishen , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Steinmaus","sequence":"additional","affiliation":[{"name":"FIRS Laboratories, RSR Ltd., Parc Ty Glas, Llanishen , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Macrae","sequence":"additional","affiliation":[{"name":"FIRS Laboratories, RSR Ltd., Parc Ty Glas, Llanishen , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Guo","sequence":"additional","affiliation":[{"name":"FIRS Laboratories, RSR Ltd., Parc Ty Glas, Llanishen , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Masiero","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Medical and Surgical Sciences , University of Padua , Padua , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Garelli","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Medical and Surgical Sciences , University of Padua , Padua , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam Dalla","family":"Costa","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Medical and Surgical Sciences , University of Padua , Padua , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Bossowski","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Endocrinology and Diabetes with a Cardiology Unit , Medical University in Bialystok , Bialystok , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jadwiga","family":"Furmaniak","sequence":"additional","affiliation":[{"name":"FIRS Laboratories, RSR Ltd., Parc Ty Glas, Llanishen , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Betterle","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Medical and Surgical Sciences , University of Padua , Padua , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard Rees","family":"Smith","sequence":"additional","affiliation":[{"name":"FIRS Laboratories, RSR Ltd., Parc Ty Glas, Llanishen , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2017,12,21]]},"reference":[{"key":"2021021304032848225_j_cclm-2017-0456_ref_001_w2aab3b7c10b1b6b1ab2b1b1Aa","unstructured":"Betterle C, Zanchetta R. Adrenalitis. In: Rose NR, Mackay IR, editors. The autoimmune diseases. London, UK: Elsevier Academic Press, 2006:501\u201314."},{"key":"2021021304032848225_j_cclm-2017-0456_ref_002_w2aab3b7c10b1b6b1ab2b1b2Aa","unstructured":"Betterle C, Zanchetta R, Presotto F. Addison disease. In: Weetman AP, editor. Autoimmune diseases in endocrinology ISBN 978-1-58829-733-4. New York, USA: Humana Press, 2008:303\u201329."},{"key":"2021021304032848225_j_cclm-2017-0456_ref_003_w2aab3b7c10b1b6b1ab2b1b3Aa","unstructured":"Betterle C, Garelli S, Presotto F, Furmaniak J. From appearance of adrenal autoantibodies to clinical symptoms of Addison\u2019s disease: natural history. In: Arvat E, Falorni A, editors. Cortisol excess and insufficiency hormone research, Vol. 46 (DOI: 10.1159\/000443872). Basel, Switzerland: Karger, 2016:133\u201345."},{"key":"2021021304032848225_j_cclm-2017-0456_ref_004_w2aab3b7c10b1b6b1ab2b1b4Aa","unstructured":"Neufeld M, Blizzard RM. Polyglandular autoimmune disease. In: Pinchera A, Doniach D, Fenzi GF, Baschieri L, editors. Symposium on autoimmune aspects of endocrine disorders. New York: Academic Press, 1980:357\u201365."},{"key":"2021021304032848225_j_cclm-2017-0456_ref_005_w2aab3b7c10b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Betterle C. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev 2002;23:327\u201364.","DOI":"10.1210\/edrv.23.3.0466"},{"key":"2021021304032848225_j_cclm-2017-0456_ref_006_w2aab3b7c10b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Husebye ES, Perheentupa J, Rautemaa R, K\u00e4mpe O. Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J Intern Med 2009;265:514\u201329.","DOI":"10.1111\/j.1365-2796.2009.02090.x"},{"key":"2021021304032848225_j_cclm-2017-0456_ref_007_w2aab3b7c10b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Coles J, Betterle C, Volpato M, Prentice L, Rees Smith B, Furmaniak J. Immunoprecipitation assay for autoantibodies to steroid 21-hydroxylase in autoimmune adrenal diseases. Clin Chem 1995;41:375\u201380.","DOI":"10.1093\/clinchem\/41.3.375"},{"key":"2021021304032848225_j_cclm-2017-0456_ref_008_w2aab3b7c10b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Tanaka H, Perez MS, Powell M, Sanders JF, Sawicka J, Chen S, et al. Steroid 21-hydroxylase autoantibodies: measurements with a new immunoprecipitation assay. J Clin Endocrinol Metab 1997;82:1440\u20136.","DOI":"10.1210\/jc.82.5.1440"},{"key":"2021021304032848225_j_cclm-2017-0456_ref_009_w2aab3b7c10b1b6b1ab2b1b9Aa","unstructured":"Betterle C, Volpato M, Pedini B, Chen S, Rees Smith B, Furmaniak J. Adrenal-cortex autoantibodies (ACA) and steroid- producing cells autoantibodies (StCA) in patients with Addison\u2019s disease: comparison between immunofluorescence and immunoprecipitation assays. J Clin Endocrinol Metab 1999;84:618\u201322."},{"key":"2021021304032848225_j_cclm-2017-0456_ref_010_w2aab3b7c10b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Betterle C, Coco G, Zanchetta R. Adrenal cortex autoantibodies in subjects with normal adrenal function. Best Pract Res Clin Endocrinol Metab 2005;19:85\u201399.","DOI":"10.1016\/j.beem.2004.11.008"},{"key":"2021021304032848225_j_cclm-2017-0456_ref_011_w2aab3b7c10b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Betterle C, Scarpa R, Garelli S, Morling L, Lazzarotto F, Presotto F, et al. Addison\u2019s disease: a survey on 633 patients in Padova. Eur J Endocrinol 2013;169:773\u201384.","DOI":"10.1530\/EJE-13-0528"},{"key":"2021021304032848225_j_cclm-2017-0456_ref_012_w2aab3b7c10b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Betterle C, Scalici C, Presotto F, Pedini B, Moro L, Rigon F, et al. The natural history of adrenal function in autoimmune patients with adrenal autoantibodies. J Endocrinol 1988;117:467\u201375.","DOI":"10.1677\/joe.0.1170467"},{"key":"2021021304032848225_j_cclm-2017-0456_ref_013_w2aab3b7c10b1b6b1ab2b1c13Aa","unstructured":"Betterle C, Volpato M, Rees Smith B, Furmaniak J, Chen S, Greggio NA, et al. I Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ-specific autoimmune diseases: markers of high progression to clinical Addison\u2019s disease. J Clin Endocrinol Metab 1997;82:932\u20138."},{"key":"2021021304032848225_j_cclm-2017-0456_ref_014_w2aab3b7c10b1b6b1ab2b1c14Aa","unstructured":"Betterle C, Volpato M, Rees Smith B, Furmaniak J, Chen S, Zanchetta R, et al. II Adrenal cortex and steroid 21-hydroxylase autoantibodies in children with organ-specific autoimmune diseases: markers of high progression to clinical Addison\u2019s disease. J Clin Endocrinol Metab 1997;82:939\u201342."},{"key":"2021021304032848225_j_cclm-2017-0456_ref_015_w2aab3b7c10b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Coco G, Dal Pra C, Presotto F, Albergoni MP, Canova C, Pedini B, et al. Estimated risk for developing autoimmune Addison\u2019s disease in patients with adrenal cortex antibodies. J Clin Endocrinol Metab 2006;91:1637\u201345.","DOI":"10.1210\/jc.2005-0860"},{"key":"2021021304032848225_j_cclm-2017-0456_ref_016_w2aab3b7c10b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Triolo TM, Armstrong TK, McFann K, Yu L, Rewers MJ, Klingensmith GJ, et al. Additional autoimmune disease found in 33% of patients at type 1 diabetes onset. Diabetes Care 2011;34:1211\u20133.","DOI":"10.2337\/dc10-1756"},{"key":"2021021304032848225_j_cclm-2017-0456_ref_017_w2aab3b7c10b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Burbelo PD, Lebovitz EE, Bren KE, Bayat A, Paviol S, Wenzlau JM, et al. Extrapancreatic autoantibody profiles in type 1 diabetes. PLoS One 2012;7:e45216.","DOI":"10.1371\/journal.pone.0045216"},{"key":"2021021304032848225_j_cclm-2017-0456_ref_018_w2aab3b7c10b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Kordonouri O, Hartmann R, Deiss D, Wilms M, Gr\u00fcters-Kieslich A. Natural course of autoimmune thyroiditis in type 1 diabetes: association with gender, age, diabetes duration, and puberty. Arch Dis Child 2015;90:411\u20134.","DOI":"10.1136\/adc.2004.056424"},{"key":"2021021304032848225_j_cclm-2017-0456_ref_019_w2aab3b7c10b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"G\u0142owi\u0144ska-Olszewska B, Michalak J, \u0141uczy\u0144ski W, Larosa M, Chen S, Furmaniak J, et al. Organ-specific autoimmunity in relation to clinical characteristics in children with long-lasting type 1 diabetes. J Pediatr Endocrinol Metab 2016;29:647\u201356.","DOI":"10.1515\/jpem-2015-0190"},{"key":"2021021304032848225_j_cclm-2017-0456_ref_020_w2aab3b7c10b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Falorni A, Chen S, Zanchetta R, Yu L, Tiberti C, Bacosi ML, et al. Measuring adrenal antibody response: interlaboratory concordance in the first international serum exchange for the determination of 21-hydroxylase autoantibodies. Clin Immunol 2011;140:291\u20139.","DOI":"10.1016\/j.clim.2011.04.012"},{"key":"2021021304032848225_j_cclm-2017-0456_ref_021_w2aab3b7c10b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Falorni A, Bini V, Betterle C, Brozzetti A, Casta\u00f1o L, Fichna M, et al. Determination of 21-hydroxylase autoantibodies: inter-laboratory concordance in the Euradrenal International Serum Exchange Program. Clin Chem Lab Med 2015;53:1761\u201370.","DOI":"10.1515\/cclm-2014-1106"},{"key":"2021021304032848225_j_cclm-2017-0456_ref_022_w2aab3b7c10b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Coutinho A, Kazatchkine MD, Avrameas S. Natural autoantibodies. Curr Opin Immunol 1995;7:812\u20138.","DOI":"10.1016\/0952-7915(95)80053-0"},{"key":"2021021304032848225_j_cclm-2017-0456_ref_023_w2aab3b7c10b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Schroeder HW Jr, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol 2010;125:S41\u201352.","DOI":"10.1016\/j.jaci.2009.09.046"},{"key":"2021021304032848225_j_cclm-2017-0456_ref_024_w2aab3b7c10b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Barker JM, Ide A, Hostetler C, Yu L, Miao D, Fain PR, et al. Endocrine and immunogenetic testing in individuals with type 1 diabetes and 21-hydroxylase autoantibodies: Addison\u2019s disease in a high risk population. J Clin Endocrinol Metab 2004;90:128\u201334.","DOI":"10.1210\/jc.2004-0874"},{"key":"2021021304032848225_j_cclm-2017-0456_ref_025_w2aab3b7c10b1b6b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Betterle C, Morlin L. Autoimmune Addison\u2019s disease. Endocr Dev 2011;20:161\u201372.","DOI":"10.1159\/000321239"},{"key":"2021021304032848225_j_cclm-2017-0456_ref_026_w2aab3b7c10b1b6b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun 2009;33:197\u2013207.","DOI":"10.1016\/j.jaut.2009.09.008"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/cclm.2018.56.issue-6\/cclm-2017-0456\/cclm-2017-0456.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2017-0456\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2017-0456\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T23:58:30Z","timestamp":1619049510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2017-0456\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,21]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,12,21]]},"published-print":{"date-parts":[[2018,5,24]]}},"alternative-id":["10.1515\/cclm-2017-0456"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2017-0456","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12,21]]}}}